Efficacy evaluation on switching to 50mg of minodronic acid hydrate in patients with osteoporosis

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2013
INTERVENTION: Patients included are to be given 50 mg of minodronic acid hydrate once every 4 weeks CONDITION: osteoporosis PRIMARY OUTCOME: Changes in bone mineral density SECONDARY OUTCOME: ‐Changes in bone metabolic markers; ‐Changes in pain symptoms; ‐Changes in abdominal symptoms; ‐Changes in patients will for medication INCLUSION CRITERIA: ‐Patients on medication with bisphosphonates (other than monodronic acid) diagnosed with primary osteoporosis ‐Patients who consent to their participation in the study and can answer questionnaires
Epistemonikos ID: 727237c56c55743d39a35315a7f030f9c41f72a5
First added on: Aug 22, 2024